Ovoca Bio (DUB:OVXA) Change In Receivables : €0.24 Mil (TTM As of Jun. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Ovoca Bio Change In Receivables?

Ovoca Bio's change in receivables for the quarter that ended in Jun. 2023 was €1.02 Mil. It means Ovoca Bio's Accounts Receivable declined by €1.02 Mil from Dec. 2022 to Jun. 2023 .

Ovoca Bio's change in receivables for the fiscal year that ended in Dec. 2022 was €-0.90 Mil. It means Ovoca Bio's Accounts Receivable increased by €0.90 Mil from Dec. 2021 to Dec. 2022 .

Ovoca Bio's Accounts Receivable for the quarter that ended in Jun. 2023 was €0.21 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Ovoca Bio's liquidation value for the six months ended in Jun. 2023 was €2.15 Mil.

Ovoca Bio Change In Receivables Historical Data

The historical data trend for Ovoca Bio's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovoca Bio Change In Receivables Chart

Ovoca Bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-0.12

-0.11

0.42

0.08

-0.90

Ovoca Bio Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial															-0.05	0.12	-0.12	-0.78	1.02

Ovoca Bio Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.24 Mil.

Ovoca Bio (DUB:OVXA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Ovoca Bio's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.211	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Ovoca Bio's accounts receivable are only considered to be worth 75% of book value:

Ovoca Bio's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.8	-	0.82	+	0.75 * 0.211	+	0.5 * 0.026
=	2.15

Ovoca Bio Change In Receivables Related Terms

Thank you for viewing the detailed overview of Ovoca Bio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovoca Bio (DUB:OVXA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovoca Bio PLC (DUB:OVXA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

OVB.GB:UK OVB:UK OVXA:Germany

Address

17 Pembroke Street Upper, Dublin, IRL, D02 AT22

Website

https://www.ovocabio.com

Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.

Ovoca Bio (DUB:OVXA) Headlines

No Headlines